Resources

Discover how Adimab’s scientific advances are shaping the future of antibody discovery. These resources are designed to inform, inspire, and advance your understanding of our platform.

Featured resource

A Versatile, Yeast-Based Synthetic Heavy Chain-Only Antibody Platform that Facilitates the Construction and Functional Screening of Multispecific CD28 T Cell Engagers
Posters

A Versatile, Yeast-Based Synthetic Heavy Chain-Only Antibody Platform that Facilitates the Construction and Functional Screening of Multispecific CD28 T Cell Engagers

Synthetic HCAb library enables rapid discovery of stable antibodies for multispecific T cell engagers

Download

Filters

Resources

Therapeutic Area

Capabilities

Resources
Rapid and efficient generation of format-diverse co-stimulatory CD28 and CD3 multispecific antibody panels for T cell engagement via complementary technologies loading="lazy">
Sun 30 Nov 2025
Posters

Rapid and efficient generation of format-diverse co-stimulatory CD28 and CD3 multispecific antibody panels for T cell engagement via complementary technologies

Engineered anti-CD3 and anti-CD28 antibodies with potent T cell activation and strong developability.
High-throughput discovery of high-affinity TCRs from synthetic yeast-based libraries loading="lazy">
Sat 15 Nov 2025
Posters

High-throughput discovery of high-affinity TCRs from synthetic yeast-based libraries

Engineered anti-CD3 heavy-chain–only antibodies with potent T cell activation and strong developability.
Adimab's yeast-based platform for high-throughput engineering of soluble TCR-Fc molecules loading="lazy">
Mon 10 Nov 2025
White papers

High-Throughput Engineering of Soluble TCRs Using Adimab’s Yeast-Based Platform

Data-driven yeast platform delivers potent, peptide-specific TCRs ready for therapeutic development.
Harnessing the Adimab Platform: Case Studies Exemplifying Our Path from De Novo Discovery to Clinical Advancement loading="lazy">
Sun 9 Nov 2025
Posters

Harnessing the Adimab Platform: Case Studies Exemplifying Our Path from De Novo Discovery to Clinical Advancement

Adimab’s yeast-based platform accelerates antibody programs from discovery to clinic

Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-Throughput Yeast-Based Platform loading="lazy">
Sun 28 Sep 2025
Posters

Rapid Engineering of Soluble T Cell Receptors for Enhanced Affinity via a High-Throughput Yeast-Based Platform

Yeast-based engineering yields high-affinity soluble TCRs, enabling potent, precise T cell therapeutics

Engineering a Panel of Potent and Developable Anti-CD3 Antibodies for Conditional Activation in the Tumor Microenvironment loading="lazy">
Fri 19 Sep 2025
Posters

Engineering a Panel of Potent and Developable Anti-CD3 Antibodies for Conditional Activation in the Tumor Microenvironment

Masked anti-CD3 antibodies activate selectively in tumors, offering potent, localized T-cell engagement
Resources